United Therapeutics jumps on patent win, FDA filing acceptance and buyback
+12.55% to $541.89 from $481.47
What moved UTHR
- A U.S. District Court in Delaware ruled that Liquidia’s Yutrepia infringed a United Therapeutics patent covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease.
- The FDA accepted United Therapeutics’ supplemental application for nebulized Tyvaso in idiopathic pulmonary fibrosis.
- The company is deploying the remaining $477.6 million of its $2 billion buyback via an accelerated share repurchase with Citibank, bringing total capital returned to about $4 billion over 2.5 years.
- Shares surged as much as 15% intraday on the combined news.
Sources: GuruFocus · StocksToTrade · CNBC